Research Analysts’ Updated EPS Estimates for September 6th (ACRV, AFMD, AFRM, AG, AKBA, AUPH, AVGO, AXSM, BRCC, BRZE)

Research Analysts’ updated eps estimates for Friday, September 6th:

Acrivon Therapeutics (NASDAQ:ACRV) had its buy rating reiterated by analysts at Piper Sandler Companies. The firm currently has a $30.00 target price on the stock.

Affimed (NASDAQ:AFMD) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $10.00 target price on the stock.

Affirm (NASDAQ:AFRM) had its hold rating reiterated by analysts at Needham & Company LLC.

First Majestic Silver (NYSE:AG) (TSE:FR) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $8.50 price target on the stock.

Akebia Therapeutics (NASDAQ:AKBA) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $7.50 target price on the stock.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $13.00 target price on the stock.

Broadcom (NASDAQ:AVGO) had its buy rating reaffirmed by analysts at Benchmark Co.. They currently have a $210.00 target price on the stock.

Broadcom (NASDAQ:AVGO) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $200.00 target price on the stock.

Axsome Therapeutics (NASDAQ:AXSM) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $107.00 target price on the stock.

BRC (NYSE:BRCC) had its buy rating reiterated by analysts at DA Davidson. DA Davidson currently has a $5.50 price target on the stock.

Braze (NASDAQ:BRZE) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $70.00 price target on the stock.

Braze (NASDAQ:BRZE) had its overweight rating reissued by analysts at Piper Sandler. They currently have a $51.00 target price on the stock.

Braze (NASDAQ:BRZE) had its buy rating reaffirmed by analysts at DA Davidson. They currently have a $65.00 target price on the stock.

Braze (NASDAQ:BRZE) had its market outperform rating reaffirmed by analysts at JMP Securities. The firm currently has a $68.00 price target on the stock.

BioXcel Therapeutics (NASDAQ:BTAI) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

Clorox (NYSE:CLX) had its neutral rating reissued by analysts at DA Davidson. DA Davidson currently has a $153.00 target price on the stock.

Connect Biopharma (NASDAQ:CNTB) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $8.00 price target on the stock.

Costco Wholesale (NASDAQ:COST) had its neutral rating reiterated by analysts at DA Davidson. The firm currently has a $780.00 target price on the stock.

Costco Wholesale (NASDAQ:COST) had its outperform rating reiterated by analysts at Telsey Advisory Group. The firm currently has a $925.00 target price on the stock.

Salesforce (NYSE:CRM) had its buy rating reiterated by analysts at Bank of America Co.. Bank of America Co. currently has a $325.00 target price on the stock.

Salesforce (NYSE:CRM) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $345.00 price target on the stock.

CrowdStrike (NASDAQ:CRWD) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $350.00 price target on the stock.

CoStar Group (NASDAQ:CSGP) had its market outperform rating reissued by analysts at JMP Securities. They currently have a $90.00 target price on the stock.

Cantaloupe (NASDAQ:CTLP) had its outperform rating reiterated by analysts at Barrington Research. The firm currently has a $10.00 target price on the stock.

Danaher (NYSE:DHR) had its outperform rating reiterated by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $300.00 price target on the stock.

DocuSign (NASDAQ:DOCU) had its hold rating reiterated by analysts at Needham & Company LLC.

eGain (NASDAQ:EGAN) had its buy rating reiterated by analysts at Roth Mkm. Roth Mkm currently has a $12.00 target price on the stock.

Elutia (NASDAQ:ELUT) had its overweight rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $10.00 target price on the stock.

Fortive (NYSE:FTV) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $77.00 price target on the stock.

Frontier Communications Parent (NASDAQ:FYBR) had its equal weight rating reiterated by analysts at Wells Fargo & Company. The firm currently has a $38.50 target price on the stock, up from their previous target price of $31.00.

Guidewire Software (NYSE:GWRE) had its hold rating reiterated by analysts at Needham & Company LLC.

Guidewire Software (NYSE:GWRE) had its buy rating reissued by analysts at DA Davidson. The firm currently has a $168.00 target price on the stock.

Hewlett Packard Enterprise (NYSE:HPE) had its neutral rating reiterated by analysts at Susquehanna. They currently have a $20.00 price target on the stock.

Jack Henry & Associates (NASDAQ:JKHY) had its sector perform rating reissued by analysts at Royal Bank of Canada. They currently have a $181.00 target price on the stock.

KalVista Pharmaceuticals (NASDAQ:KALV) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $20.00 target price on the stock.

KalVista Pharmaceuticals (NASDAQ:KALV) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $32.00 price target on the stock.

Lancaster Colony (NASDAQ:LANC) had its hold rating reaffirmed by analysts at Benchmark Co..

Lantronix (NASDAQ:LTRX) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $7.00 target price on the stock.

Metagenomi (NASDAQ:MGX) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

UiPath (NYSE:PATH) had its equal weight rating reissued by analysts at Morgan Stanley. The firm currently has a $15.00 price target on the stock.

UiPath (NYSE:PATH) had its sector perform rating reiterated by analysts at Royal Bank of Canada. The firm currently has a $16.00 target price on the stock.

UiPath (NYSE:PATH) had its hold rating reissued by analysts at Needham & Company LLC.

Phathom Pharmaceuticals (NASDAQ:PHAT) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $26.00 target price on the stock.

Planet Labs PBC (NYSE:PL) had its market outperform rating reiterated by analysts at JMP Securities. The firm currently has a $4.00 price target on the stock.

TransCode Therapeutics (NASDAQ:RNAZ) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $3.00 price target on the stock.

SecureWorks (NASDAQ:SCWX) had its hold rating reissued by analysts at Needham & Company LLC.

Select Medical (NYSE:SEM) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $48.00 price target on the stock.

Shoals Technologies Group (NASDAQ:SHLS) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $11.00 target price on the stock.

Skye Bioscience (NASDAQ:SKYE) had its overweight rating reissued by analysts at Cantor Fitzgerald. They currently have a $14.00 target price on the stock.

Skye Bioscience (NASDAQ:SKYE) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $14.00 price target on the stock.

Smartsheet (NYSE:SMAR) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $57.00 target price on the stock.

Smartsheet (NYSE:SMAR) had its buy rating reaffirmed by analysts at DA Davidson. The firm currently has a $55.00 price target on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $181.00 target price on the stock.

SoundThinking (NASDAQ:SSTI) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $20.00 target price on the stock.

Toro (NYSE:TTC) had its market perform rating reaffirmed by analysts at Northland Securities. They currently have a $100.00 price target on the stock.

Uber Technologies (NYSE:UBER) had its buy rating reaffirmed by analysts at Truist Financial Co.. Truist Financial Co. currently has a $88.00 target price on the stock.

Unicycive Therapeutics (NASDAQ:UNCY) had its speculative buy rating reaffirmed by analysts at Benchmark Co.. They currently have a $3.00 target price on the stock.

Vera Therapeutics (NASDAQ:VERA) had its overweight rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $107.00 target price on the stock.

Vor Biopharma (NYSE:VOR) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $17.50 price target on the stock.

Vor Biopharma (NYSE:VOR) had its market outperform rating reissued by analysts at JMP Securities. JMP Securities currently has a $12.00 price target on the stock.

Ziff Davis (NASDAQ:ZD) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $95.00 target price on the stock.